Press releases | Deinove

30.03.2020

In a climate of economic and industrial uncertainty, the collaboration agreement between Sharon Laboratories and Deinove will not be signed

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...

20.01.2020

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

26.09.2019

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

09.07.2019

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

28.03.2019

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...

18.02.2019

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

21.11.2018

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...

27.09.2018

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...

15.06.2018

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...

23.05.2018

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...